Cancer drug interaction study completed in healthy volunteers
NCT ID NCT05906836
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at how the cancer drug selpercatinib changes the levels of rosuvastatin, a cholesterol-lowering drug, in the blood. It involved 28 healthy adults and lasted about 26 days. The goal was to understand any drug interactions and check safety when both are taken together.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- selpercatinib and rosuvastatin
- What this could lead to
- If successful, this study could help doctors understand how to safely combine selpercatinib with rosuvastatin in future treatments.
- What could go wrong
- This is an early-stage study in healthy people, not patients. Results may not apply to those with cancer or other conditions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Labcorp Clinical Research LP
Dallas, Texas, 75247, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test